title: Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
abstract: The first-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regimens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of Sustained Virological Response in both naive and treatment-experienced patients with chronic genotype-1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly variable and results from the combination of multiple factors related to the characteristics of patient, viral status and liver disease. The recommendations presented are promoted by the Italian Association for the Study of the Liver, with the aim to help the physician in the decision-making process as well as to manage patients during treatment with triple therapy.
authors.affiliation: AISF Coordinating Committee.
authors.forename: Barbara
authors.initials: B
authors.lastname: Coco
authors.affiliation: AISF Coordinating Committee. Electronic address: info@webaisf.org.
authors.forename: Paolo
authors.initials: P
authors.lastname: Caraceni
authors.affiliation: AISF Consulting Committee on the New Antiviral Hepatitis C Drugs.
authors.forename: Alessio
authors.initials: A
authors.lastname: Aghemo
authors.affiliation: AISF Consulting Committee on the New Antiviral Hepatitis C Drugs.
authors.forename: Davide
authors.initials: D
authors.lastname: Bitetto
authors.affiliation: AISF Consulting Committee on the New Antiviral Hepatitis C Drugs.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Bruno
authors.affiliation: AISF Coordinating Committee.
authors.forename: Alessia
authors.initials: A
authors.lastname: Ciancio
authors.affiliation: AISF Coordinating Committee.
authors.forename: Marco
authors.initials: M
authors.lastname: Marzioni
authors.affiliation: AISF Consulting Committee on the New Antiviral Hepatitis C Drugs.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Petta
authors.affiliation: AISF Coordinating Committee.
authors.forename: Maria
authors.initials: M
authors.lastname: Rendina
authors.affiliation: AISF Coordinating Committee.
authors.forename: Luca
authors.initials: L
authors.lastname: Valenti
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004337:Drug Carriers / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D004337:Drug Carriers; D016898:Interferon-alpha; D009842:Oligopeptides; D011480:Protease Inhibitors; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline
keywords: Boceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir